Pre-Course of the European Academy of Allergy and Clinical Immunology

This EAACI-sponsored symposium will provide four state-of-the-art lectures from global leaders in allergic disease pathways and how they are modulated by both established treatments, such as allergen immunotherapy and novel biologics. Following this mini-symposium, attendees will be up to date on our current understanding of allergic disease classifications, including the newly proposed EAACI additions. Attendees will improve their understanding of the in vivo consequences of treatments with monoclonal antibodies targeting the IL-4/IL13 pathway, insights that help us to understand the non-redundant roles of these pivotal TH2 cytokines. The latest science of how allergen immunotherapy slowly shifts allergen-specific responses from inflammatory to tolerant, highlighting roles for isotype switching, regulatory T-cells, and phenotypic-alteration of antigen-presenting cells will be covered. Finally, the latest immunopathogenic models in drug hypersensitivity will be discussed, with a particular focus on non-immune and immune pathways that underpin overlapping clinical phenotypes of allergy.

Chairs:
Jonny PETER, South Africa
Cezmi A. AKDIS, Switzerland

12:45 - 13:00  Nomenclature of Allergic Diseases and hypersensitivity reactions.
Ioana AGACHE, Romania

12:45 - 13:00  Discussion

13:00 - 13:45  Immunomodulation by biologics: Direct in vivo evidence for the immunologic effects of the blocking of IL-4, IL-5 and IL-13 signaling
Ioana AGACHE, Romania

13:45 - 14:00  Discussion

14:00 - 14:45  Molecular mechanisms of allergen-specific immunotherapy
Mohamed H. SHAMJI, United Kingdom

14:45 - 15:00  Discussion

15:00 - 15:45  Immune pathogenesis of different phenotypes of drug hypersensitivity
María JOSÉ TORRES, Spain

15:45 - 16:00  Discussion